Aortic Stent Grafts Market

The global aortic stent grafts market is expected to be valued at US$3.80 billion in 2026 and is projected to reach US$5.45 billion by 2033, growing at a CAGR of 5.3% between 2026 and 2033.

The U.S. Food and Drug Administration's Breakthrough Device Designation pathway, which accelerated approvals for next-generation fenestrated and branched endografts from Medtronic plc and Cook Medical between 2022 and 2024, stands as the primary regulatory catalyst sustaining this trajectory. Per World Health Organization projections, adults aged 60 and above will represent 22% of the global population by 2050, with aortic aneurysm prevalence closely correlated to this cohort, making the 5.3% CAGR a conservative baseline rather than an optimistic ceiling.

• North America's structural leadership in the aortic stent grafts market representing US$1.67 billion in 2026 is reinforced by the Society for Vascular Surgery's active national quality registry, which creates a self-reinforcing cycle of outcomes transparency, physician confidence, and sustained EVAR procedure volume growth that other regions have yet to replicate at scale.
• Asia Pacific's 6.8% CAGR makes it the decisive growth theatre for the forecast period, with China's National Medical Products Administration regulatory acceleration and India's Ayushman Bharat scheme together unlocking hundreds of millions of previously underserved patients whose rising access to tertiary vascular care will translate into compounding device volume gains through 2033.
• Abdominal Aortic Stent Grafts dominate with a 47.0% share, anchored by a robust evidence base, established CMS reimbursement pathways, and a growing cohort of trained implanting physicians structural pillars that will sustain the segment's leadership even as complex anatomy solutions gain share at the clinical margin.
• Ambulatory Surgical Centers are the fastest-growing end-user channel, catalysed by CMS procedural coverage expansion in 2024; manufacturers that proactively develop ASC-optimised device configurations specifically thinner delivery profiles and simplified deployment mechanisms will capture disproportionate share as case migration from hospitals to outpatient settings accelerates through 2028.
• The custom fenestrated endograft opportunity targeting the estimated 30–40% of aneurysm patients excluded from standard EVAR represents the highest-margin strategic growth pocket in the aortic stent grafts market, accessible primarily to manufacturers with IDE-approved clinical programmes and dedicated custom manufacturing lines, where Cook Medical's Bloomington facility expansion positions it ahead of competitors in near-term capacity.

• Accelerating Adoption of Endovascular Aneurysm Repair over Open Surgery

Endovascular aneurysm repair (EVAR) now accounts for the majority of elective abdominal aortic aneurysm repairs across high-income markets, displacing open surgical approaches that carry significantly higher 30-day mortality rates a clinical shift that directly expands addressable demand for aortic stent grafts at every hospital system procurement cycle.

The Society for Vascular Surgery updated its clinical practice guidelines in 2022 to recommend EVAR as the preferred approach for anatomically suitable patients, while Endologix LLC received FDA clearance for its Alto abdominal stent graft system in 2023, broadening the range of aortic neck anatomies treatable endovascularly.

As vascular surgery programs in mid-tier hospital systems in Europe and North America complete their EVAR capability build-outs through 2026–2028, per-facility device volumes are expected to rise, rewarding manufacturers with broad device diameter portfolios and robust clinical support infrastructure.

• High Device Cost and Reimbursement Pressure in Price-Sensitive Markets

Complex fenestrated and branched aortic stent graft systems carry average selling prices ranging from approximately US$ 15,000 to US$ 45,000 per device, creating significant budget friction for public health systems operating under fixed diagnosis-related group reimbursement structures, particularly across Southern and Eastern Europe where hospital procurement budgets remain constrained.

The European Union's Medical Device Regulation (MDR 2017/745), which became fully applicable in May 2021 with phased compliance extensions running through 2027, imposes substantially elevated clinical evidence requirements that extend time-to-market and increase pre-commercialisation costs by an estimated 20–30% for Class III implantable devices, according to MedTech Europe assessments.

Smaller independent manufacturers face a proportionally higher compliance cost burden relative to revenue, creating a structural disadvantage versus large-cap incumbents who can amortise regulatory costs across broader device portfolios.

• Expansion into Emerging Markets via Locally Manufactured and Cost-Optimised Devices

Investors and device manufacturers should prioritise localised manufacturing partnerships in China, India, and Brazil, where aortic disease burden is rising sharply but per-procedure device cost remains the primary adoption barrier separating addressable from served market.

MicroPort Scientific Corporation launched its Aegis thoracic endograft system across Southeast Asian and Middle Eastern markets between 2023 and 2024, demonstrating that regional manufacturing and targeted pricing can unlock previously inaccessible hospital procurement budgets in cost-sensitive environments.

For this opportunity to fully materialise, manufacturers must secure domestic regulatory approvals particularly under India's Central Drugs Standard Control Organisation (CDSCO) Class C device pathway and establish distributor networks capable of providing the clinical support that complex aortic procedures demand.

• Product Type Analysis

Abdominal aortic stent graft commands the leading position in the aortic stent grafts market, accounting for 47.0% of total market revenue in 2026, equivalent to US$1.79 billion, driven by the high prevalence of infrarenal abdominal aortic aneurysms in the ageing male population over 65 the primary demographic where screening programmes such as the U.K. National Health Service's abdominal aortic aneurysm screening programme actively identify and refer patients. Vascular surgery departments at major academic medical centres such as the Cleveland Clinic and Mayo Clinic routinely select EVAR with abdominal stent graft systems as the first-line approach for elective repair, sustaining high and predictable device volumes year-round through structured case scheduling. The segment's dominance reflects mature clinical evidence, well-established reimbursement pathways, and a deep installed base of trained implanting physicians structural factors that competitors in adjacent segments cannot rapidly replicate.

Thoracic aortic stent graft is the fastest-growing product type, propelled by expanded clinical indications covering both thoracic aortic aneurysms and type B aortic dissections, where endovascular repair offers a less invasive alternative to thoracotomy. W. L. Gore & Associates received FDA approval for expanded instructions for use of its GORE TAG thoracic endoprosthesis in 2023, broadening anatomical eligibility and accelerating adoption across U.S. thoracic surgery and vascular hybrid programmes.

• End-User Analysis

Hospitals dominate the aortic stent grafts market end-user landscape, representing 68.0% of total demand in 2026, equivalent to US$2.58 billion, because complex aortic endovascular procedures require hybrid operating theatres equipped with fixed angiographic imaging systems, specialised perfusion teams, and intensive care backup infrastructure exclusively available in full-service hospital environments. Tertiary referral hospitals and Level I trauma centres manage the highest-acuity aortic cases, including emergent ruptured aneurysm repairs and acute type B dissections, where access to on-site blood banking, cardiac surgery, and interventional radiology suites makes a hospital setting not merely preferable but procedurally mandatory. The clinical and infrastructure requirements of aortic stent graft implantation mean hospitals will retain pricing leverage with device manufacturers and sustain their dominant share through the forecast period.

Ambulatory surgical centers (ASCs) represent the fastest-growing end-user segment, catalysed by the Centers for Medicare & Medicaid Services' 2024 update to its ASC-covered procedures list, which expanded reimbursement for select lower-complexity EVAR cases in outpatient settings, enabling centres such as those operating under the Surgical Care Affiliates network to begin scheduling elective endovascular aneurysm repairs. As device profiles narrow and post-procedural recovery protocols shorten, a growing subset of anatomically straightforward infrarenal aneurysm cases is shifting toward ASC settings that offer faster scheduling and lower overhead costs for both patients and payers.

• North America Aortic Stent Grafts Market Trends and Insights

North America accounts for 44.0% of the aortic stent grafts market in 2026, representing US$1.67 billion, sustained by the region's combination of high procedure reimbursement rates, mature vascular surgery infrastructure, and an active regulatory environment that consistently generates new device approvals ahead of other geographies.

The Inflation Reduction Act of 2022 did not directly target device pricing, but its downstream pressure on healthcare system cost structures has intensified hospital value analysis committee scrutiny on implant spend, nudging procurement toward bundled pricing arrangements with tier-1 suppliers. With the U.S. baby boomer cohort fully entering the peak aneurysm-risk age bracket through 2030, North America's volume growth trajectory is structurally secured for the duration of the forecast period.

U.S. Aortic Stent Grafts Market Size

The U.S. aortic stent grafts market represents 84.0% of the North America regional market in 2026, equivalent to US$1.40 billion, driven by the highest per-capita rate of EVAR procedures among developed nations and a reimbursement environment where Medicare covers elective EVAR under MS-DRG 237 and 238, providing hospitals with predictable procedural revenue.

The ongoing Vascular Quality Initiative registry, administered by the Society for Vascular Surgery, tracks real-world outcomes across hundreds of U.S. implanting centres, creating a continuous quality-improvement feedback loop that supports clinical confidence in EVAR adoption and reinforces device volume at high-performing programmes.

• Asia Pacific Aortic Stent Grafts Market Trends and Insights

Asia Pacific accounts for 31.0% of the aortic stent grafts market in 2026, representing US$1.18 billion, and is the fastest-growing region at a CAGR of 6.8%, driven by rapidly expanding vascular intervention capacity in China, Japan, and India alongside a demographic age wave that is producing a sharply rising aortic disease burden across all three markets.

China's National Medical Products Administration (NMPA) has accelerated approval timelines for Class III cardiovascular devices under its 2021 Medical Device Supervision and Administration Regulations, reducing average approval cycles by an estimated six to twelve months and enabling both domestic and multinational manufacturers to launch newer-generation devices faster than previously possible. The region's above-market growth rate makes Asia Pacific the single most strategically important expansion theatre for global aortic stent graft manufacturers through 2033.

China Aortic Stent Grafts Market Size

The China aortic stent grafts market represents 36.0% of the Asia Pacific regional market in 2026, equivalent to US$0.42 billion, underpinned by the country's rapidly expanding hospital infrastructure the National Health Commission of China reported over 36,000 registered hospitals nationwide as of 2023 and a rising incidence of hypertension-related aortic disease in the urban population over 60.

MicroPort Scientific Corporation's domestic endograft platforms, manufactured in Shanghai, benefit from government procurement preferences under China's "Made in China 2025" medical device localisation initiative, positioning the company to capture incremental share as public hospital systems prioritise domestically sourced implants.

Japan Aortic Stent Grafts Market Size

The Japan aortic stent grafts market represents 22.0% of the Asia Pacific regional market in 2026, equivalent to US$0.26 billion, supported by Japan's status as one of the world's most rapidly ageing societies the Statistics Bureau of Japan confirmed adults aged 65 and over constitute 29.1% of the total population as of 2023.

Terumo Corporation, headquartered in Tokyo, has strengthened its domestic vascular intervention portfolio through continued investment in its RelayNBS thoracic stent graft system, giving Japan a locally anchored competitive device option that reduces dependence on imported platforms and supports domestic procedural growth.

India Aortic Stent Grafts Market Size

The India aortic stent grafts market represents 18.0% of the Asia Pacific regional market in 2026, equivalent to US$0.21 billion, with growth anchored by the rapid expansion of tertiary cardiac and vascular care capacity in metropolitan centres the National Health Authority of India's Ayushman Bharat PM-JAY scheme has enrolled over 550 million beneficiaries, gradually extending coverage toward high-cost vascular procedures and unlocking a previously inaccessible patient population.

As domestic medical device manufacturing scales under the Production Linked Incentive (PLI) Scheme for Medical Devices announced by the Ministry of Chemicals and Fertilizers, locally produced lower-cost aortic stent graft options are expected to enter clinical use by 2027, materially expanding the addressable treated population.

The global aortic stent grafts market operates as a moderately concentrated oligopoly, with Medtronic plc, W. L. Gore & Associates, and Cook Medical collectively commanding an estimated 55–60% of global revenue, competing primarily on clinical evidence depth, device portfolio breadth, and vascular surgery programme support services rather than price alone. The dominant strategic theme across tier-1 players is portfolio extension into complex anatomies fenestrated, branched, and physician-modified configurations which simultaneously raises the technical barrier to entry and deepens institutional customer relationships.

MicroPort Scientific Corporation represents the most credible disruptive entrant, leveraging Chinese manufacturing economics and NMPA-accelerated approvals to undercut Western incumbents on price in Asia Pacific, while Bentley InnoMed GmbH pursues a focused niche strategy in the European thoracic segment. Winners in this market consistently invest in multi-year post-market clinical programmes; laggards that underinvest in outcomes data generation lose ground in hospital value analysis committee evaluations, regardless of short-term pricing competitiveness.

• Medtronic plc
• W. L. Gore & Associates, Inc.
• Cook Medical
• Terumo Corporation
• Endologix LLC
• MicroPort Scientific Corporation
• Bentley InnoMed GmbH
• Getinge AB
• Cardinal Health, Inc.

By Product Type

• Abdominal Aortic Stent Graft
• Thoracic Aortic Stent Graft
• Aortic Dissection
• Aortic Trauma
• Others

By End-User

• Hospitals
• Vascular Centers
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Regions

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa